Cidara Therapeutics, Inc. announced on March 17, 2025, the publication of preclinical data for its influenza DFC, CD388, in the peer-reviewed scientific journal Nature Microbiology. The article is titled 'Drug-Fc Conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.'
The published data highlights CD388's potential as a potent, universal preventative for influenza A and B in both healthy and high-risk populations, irrespective of immune status. This scientific validation supports the broad applicability of the Cloudbreak DFC platform.
Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, stated that this publication, combined with existing clinical data, further validates the Cloudbreak DFC platform and CD388's potential for universal protection against seasonal and pandemic influenza strains. The efficacy of CD388 is driven by the intrinsic antiviral activity of the drug.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.